Biotech Values

[jq1234]

I haven't gone through NVO 3Q2014 result yet. The title of article doesn't seem to match content of article which simply said NVO will decide in 1H2015 whether to submit interim result or final result from ongoing Tresiba study in response to CRL.

It also doesn't seem SNY's basal insulin projection affecting NVO's Levemir much, probably because large portion of Lantus growth has come from sharp price increases - 3 double digit increases since 2013.